CD44 is a cell surface glycoprotein that plays a crucial role in numerous cellular processes, making it a subject of extensive scientific interest. This multifunctional receptor is involved in cell adhesion, migration, and signaling, modulating interactions between cells and their microenvironment. CD44 acts as a receptor for hyaluronic acid and various extracellular matrix components, enabling cell adhesion and migration during tissue development and repair. Additionally, CD44 interacts with growth factors and cytokines, influencing intracellular signaling pathways that regulate cell survival, proliferation, and differentiation. Due to its diverse functions, CD44 is implicated in several diseases. In cancer, CD44 is associated with tumor cell invasion, metastasis, and resistance to therapy. CD44's involvement in inflammation and immune response makes it relevant in autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease. Furthermore, CD44's role in tissue regeneration and wound healing has implications for fibrotic diseases. According to the World Health Organization (WHO), cancer is a leading cause of mortality worldwide, with an estimated 10 million cancer-related deaths in 2020. Thus, understanding CD44's functions in disease pathogenesis could pave the way for targeted therapies addressing these critical health challenges. This will boost the CD44 sales in the forecast period. Companies are trying to find new and novel molecules to prevent and cure these diseases. The development and launch of newer products by the market players will significantly enhance the CD44 market over the forecast years.
Several of these inhibitors are on the market, while many are in ongoing clinical trials. Companies in their pipelines have 12 products in various stages of clinical trials - 2 products are in Phase 2, and 5 products are in Phase 1 of the clinical trials.
Drugs in Pipeline
- CA102N
- A6
- ALM201
- AMC303
- AMT-116 ADC
- MD 101
- SPL-108
Clinical Activity and Developments of CD44
As of July 2023, 12 products for 51 diseases are in clinical trials. For instance, Multitude Therapeutics Inc. is conducting a Phase 1 clinical trial to study AMT-116 in patients with Advanced Solid Tumors that is expected to be completed by July 2025.
|
Molecule Name |
Number of studies |
|
CA102N |
2 |
|
A6 |
1 |
|
ALM201 |
1 |
|
AMC303 |
1 |
|
AMT-116 ADC |
1 |
Target Indication Analysis of CD44
CD44, a versatile cell surface glycoprotein, finds diverse applications in various medical indications, with some areas showcasing particular prominence. One of the most significant uses of CD44 is in cancer research and treatment. Its involvement in tumor cell invasion, metastasis, and resistance to therapy makes it an attractive target for developing novel anti-cancer therapies. Additionally, CD44's crucial role in tissue regeneration and wound healing has garnered interest in the field of regenerative medicine, where it holds promise for promoting tissue repair and regeneration. Furthermore, CD44's participation in inflammation and immune response has led to its exploration as a potential therapeutic target in autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease. In the context of infectious diseases, CD44's interactions with pathogens and immune cells have been studied for their implications in viral infections and immune response modulation. Understanding CD44's functions in these disease contexts offers opportunities for targeted interventions that could significantly impact patients' outcomes and quality of life.
CD44 Regional Analysis
CD44 Market
According to the American Society of Clinical Oncology report, an estimated 8,830 people, including 4,850 men and 3,980 women, will be diagnosed with Hodgkin Lymphoma in 2023. In 2020, an estimated 83,087 people were diagnosed with it globally. It affects children and adults and is the most commonly diagnosed disease in the age group of 15 to 19. American Cancer Society estimated that about 80,500 people, including 44,880 males and 35,670 females, will be diagnosed with non-Hodgkin lymphoma (NHL) in the USA in 2023. NHL may occur at any age, with men being affected more than the females. The incidence of Lymphoma is decreasing by 1% every year, but there are still many cases of it globally, and it poses a great opportunity in the CD44 market for local players.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
Currently, no CD44 molecule has been FDA-approved.
These are being used in various indications like Lymphomas and Leukemias
Holy Stone Healthcare, Angstrom Pharmaceuticals, Almac Discovery, and Amcure GmbH are some of the major market players for CD44.
The rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and changing lifestyles leading to different types of cancers like Lymphoma and Leukemia are the critical opportunities for CD44 in the market.
- Holy Stone Healthcare
- Angstrom Pharmaceuticals
- Almac Discovery
- Amcure GmbH
- Multitude Therapeutics
- MaimoniDex RA
- Splash Pharmaceuticals